Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Difference Hydrodissection for CTS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03031041
Recruitment Status : Completed
First Posted : January 25, 2017
Last Update Posted : October 31, 2019
Sponsor:
Information provided by (Responsible Party):
Yung-Tsan Wu, Tri-Service General Hospital

Tracking Information
First Submitted Date  ICMJE January 21, 2017
First Posted Date  ICMJE January 25, 2017
Last Update Posted Date October 31, 2019
Actual Study Start Date  ICMJE January 25, 2017
Actual Primary Completion Date August 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 31, 2018)
Change from baseline of severity of symptoms and functional status on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
Boston carpal tunnel syndrome questionnaire (BCTQ) is a frequently used patient-based questionnaire for measurement of CTS which encompasses two components. In total, 11 questions and 8 items were evaluated to rate the symptom severity scale (SSS) and functional status scale (FSS), respectively. Both subscales range from 1 to 5 with a higher score indicating a higher degree of disability. The mean of total SSS and FSS divided with each item score were used for further analysis.
Original Primary Outcome Measures  ICMJE
 (submitted: January 21, 2017)
Change from baseline of pain on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
Using the Visual analog scale (VAS) to measure the pain scale before treatment and multiple time frame after treatment.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 31, 2018)
  • Change from baseline of pain on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Digital pain severity or paresthesia/dysthesia was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.
  • Change from baseline of cross-sectional area of the median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Using the musculoskeletal sonogram to measure the cross-sectional area of the median nerve before treatment and multiple time frame after treatment.
  • Change from baseline of conduction velocity, amplitude of median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Electrophysiological study of the median nerve before treatment and multiple time frame after treatment.
  • Change from baseline of finger pinch on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    The finger pinch strength was measured using dynamometer (Fabrication Enterprises Inc., USA). The subject was seated with shoulder adducted and neutrally rotated with the elbow flexed at 90°. The forearm and wrist were positioned in a neutral position for the palmar pinch
Original Secondary Outcome Measures  ICMJE
 (submitted: January 21, 2017)
  • Change from baseline of severity of symptoms and functional status on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Using the Boston Carpal Tunnel Syndrome Questionnaire to measure the severity of symptoms and functional status before treatment and multiple time frame after treatment.
  • Change from baseline of cross-sectional area of the median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Using the musculoskeletal sonogram to measure the cross-sectional area of the median nerve before treatment and multiple time frame after treatment.
  • Change from baseline of conduction velocity, amplitude of median nerve on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    Electrophysiological study of the median nerve before treatment and multiple time frame after treatment.
  • Change from baseline of finger pinch on 2nd week, 1st, 2nd, 3rd and 6th month after injection [ Time Frame: Pre-treatment, 2nd week, 1st, 2nd, 3rd and 6th month after injection ]
    The finger pinch strength was measured using dynamometer (Fabrication Enterprises Inc., USA). The subject was seated with shoulder adducted and neutrally rotated with the elbow flexed at 90°. The forearm and wrist were positioned in a neutral position for the palmar pinch
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Comparison of Difference Hydrodissection for CTS
Official Title  ICMJE Comparison of Difference Hydrodissection Technique in Patients With Carpal Tunnel Syndrome
Brief Summary Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. Rather than other progressive disease, CTS is characterized by remission and recurrence. The hydrodissection could decrease the entrapment of nerve to restore blood supply. Despite the hydrodissection was pervasively used in clinical practice, current researches contain small participant without control group or randomized leading to foreseeable selection bias. The investigators design a randomized, double-blind, controlled trial to assess the effect of different method of ultrasound-guided hydrodissection in patients with CTS.
Detailed Description After obtaining written informed consent, patients with bilateral CTS will been randomized into intervention and control group. Participants in short-axis group received one-dose ultrasound-guided hydrodissection with short-axis approach and long-axis group received one-dose ultrasound-guided injection with long-axis approach. No additional treatment after injection through the study period. The primary outcome is Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and secondary outcomes include visual analog scale (VAS), cross-sectional area (CSA) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. The evaluation was performed pretreatment as well as on the 2nd week, 1st, 2nd, 3rd and 6th month after the treatment.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Carpal Tunnel Syndrome
Intervention  ICMJE
  • Procedure: Ultrasound-guided short-axis hydrodissection with 5cc normal saline
    Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
  • Procedure: Ultrasound-guided long-axis hydrodissection with 3cc normal saline
    Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
Study Arms  ICMJE
  • Experimental: Short-axis hydrodissection
    Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
    Intervention: Procedure: Ultrasound-guided short-axis hydrodissection with 5cc normal saline
  • Active Comparator: Long-axis hydrodissection
    Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
    Intervention: Procedure: Ultrasound-guided long-axis hydrodissection with 3cc normal saline
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 29, 2019)
47
Original Estimated Enrollment  ICMJE
 (submitted: January 21, 2017)
40
Actual Study Completion Date  ICMJE August 30, 2019
Actual Primary Completion Date August 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age between 20-80 year-old.
  • Diagnosis was confirmed using an electrophysiological study

Exclusion Criteria:

  • Cancer
  • Coagulopathy
  • Pregnancy
  • Inflammation status
  • Cervical radiculopathy
  • Polyneuropathy, brachial plexopathy
  • Thoracic outlet syndrome
  • Previously undergone wrist surgery or steroid injection for CTS
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03031041
Other Study ID Numbers  ICMJE Difference PIT for CTS
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Responsible Party Yung-Tsan Wu, Tri-Service General Hospital
Study Sponsor  ICMJE Tri-Service General Hospital
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Yung-Tsan Wu, MD Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
PRS Account Tri-Service General Hospital
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP